Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 12Solid Tumor 6Advanced Solid Tumors 5Sarcoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Small Cell Lung Carcinoma 2Mesothelioma 2Melanoma 2Carcinoma, Renal Cell 2Anus Neoplasms 2Advanced Solid Tumour 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Solid Tumor, Adult 1Neoplasms, Unknown Primary 1Metastatic Solid Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumors 1MSI-H/dMMR Solid Tumors 1MSI-H Colorectal Cancer 1Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced and Metastatic Solid Tumors 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × tislelizumab × Other solid neoplasm × Clear all
NCT05441046 2022-07-06

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
120 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡